Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC
Tomasz Beer, MD, OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, discusses results from a network meta-analysis comparing... Read More
Optimal therapy for high-risk localized prostate cancer remains unclear
Among the many approaches and treatment combinations available for men with high-risk localized prostate cancer, the optimal strategy remains to... Read More
ASCO Issues New Guidelines for Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer
The American Society of Clinical Oncology (ASCO) has released new guidelines to address abiraterone or docetaxel with androgen-deprivation therapy (ADT)... Read More
First-Line Docetaxel Improves QoL, Proves Cost-Effective in Prostate Cancer
The addition of docetaxel to first-line long-term hormone therapy in prostate cancer improves overall health-related quality of life, reduces the... Read More
Focal Therapy for Primary Localized Prostate Cancer Remains Investigational
Focal therapy for primary localized prostate cancer should remain investigational pending further study, according to a 2018 European Association of... Read More
Biopsies Often Not Useful 2 Years After Radiotherapy for Prostate Cancer
Two-year post-radiotherapy biopsies do not predict survival for most men with prostate cancer, according to results from the RT01 trial.... Read More